The U.S. Food and Drug Administration (FDA) has authorized Philip Morris's Zyn nicotine pouches to be marketed with claims that they reduce the risk of certain smoking-related diseases compared to cigarettes.
Key Details
- The FDA decision allows 20 Zyn products to carry a modified-risk claim. Switching from cigarettes to Zyn pouches is stated to lower the risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.
- Zyn pouches contain nicotine but not tobacco. They are placed between the user's gum and lip.
- The authorization does not mean Zyn is safe. The FDA states there is no safe tobacco product and that youth should not use tobacco products.
- The FDA had previously authorized the same 20 Zyn products for sale in January 2025, but that authorization did not permit risk-reduction marketing claims.
Background
- The decision represents a regulatory win for Philip Morris as cigarette sales decline and the company invests in smoke-free products.
- The Trump administration has taken a more industry-friendly approach to nicotine products, including creating a pathway for some flavored e-cigarettes and nicotine pouches to remain on the market during FDA review.
- The White House did not immediately comment on the decision.
Political and Cultural Context
- Zyn has become a cultural marker in conservative politics. Former Fox News host Tucker Carlson popularized the brand before launching his own nicotine pouch brand, Alp.
- Health and Human Services Secretary Robert F. Kennedy Jr. uses nicotine pouches, per The Wall Street Journal.
- President Donald Trump reversed his earlier stance on flavored e-cigarettes and promised to "save vaping" during the 2024 campaign.
Products Covered
The authorized products include Zyn Chill, Cinnamon, Citrus, Coffee, Cool Mint, Menthol, Peppermint, Smooth, Spearmint, and Wintergreen, each in 3-milligram and 6-milligram nicotine strengths.